Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vorinostat + lutetium Lu 177 vipivotide tetraxetan
- Development stage
- Unknown
- Lead developer
- Fred Hutch
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Oral, Intravenous
01
Overview
This combination therapy consists of vorinostat, a histone deacetylase (HDAC) inhibitor, and lutetium Lu 177 vipivotide tetraxetan, a PSMA-targeted radioligand therapy. In the context of the VALOR phase II trial conducted by Fred Hutchinson Cancer Center, vorinostat is utilized as an epigenetic priming agent to upregulate the expression of prostate-specific membrane antigen (PSMA) in patients with PSMA-low metastatic castration-resistant prostate cancer (mCRPC). By increasing PSMA density on tumor cells, vorinostat aims to enhance the binding and therapeutic efficacy of the subsequent radiopharmaceutical, 177Lu-PSMA-617, which delivers targeted beta-particle radiation to the cancer cells.
- Brand names
- ZolinzaPluvicto
- Other names
- vorinostat + 177Lu-PSMA-617vorinostat + lutetium (177Lu) vipivotide tetraxetan
02
Targets
PSMA (Prostate-specific membrane antigen)HDAC (HDAC family)
Beyond the preview
Go deeper on vorinostat + lutetium Lu 177 vipivotide tetraxetan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vorinostat + lutetium Lu 177 vipivotide tetraxetan.